Cost-effectiveness of school-based asthma screening in an urban setting
Background Much has been done to promote population-based childhood asthma screening; however, concerns remain regarding its cost-effectiveness. Objectives To conduct a cost-effectiveness analysis of school-based asthma screening strategies. Methods A 5 health state Markov approach (symptom-free, sy...
Gespeichert in:
Veröffentlicht in: | Journal of allergy and clinical immunology 2010-03, Vol.125 (3), p.643-650.e12 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background Much has been done to promote population-based childhood asthma screening; however, concerns remain regarding its cost-effectiveness. Objectives To conduct a cost-effectiveness analysis of school-based asthma screening strategies. Methods A 5 health state Markov approach (symptom-free, symptom, exacerbation recovery, emergency department, and hospitalization day) was used to evaluate school-based screening in a simulated population of urban elementary-age school children. Two questionnaire and 2 multistage strategies incorporating spirometry or spirometry with exercise testing were evaluated from the societal perspective by using 365 daily cycles. The outcome was 2006 dollars per quality-adjusted life year (QALY). Results The most efficient strategy identified children with previously diagnosed but poorly controlled asthma at a cost of $150,000 per QALY (95% CI, $65,800-$318,000). Uncertainty surrounding the cost-effectiveness estimate was primarily a result of the symptom day preference weight estimate (44%), the probability of confirmation after screening (17%), the adequacy of asthma control in the population (9%), and the estimated treatment effect on symptoms (6%). Screening generated an additional 21 symptom-free day equivalents per child identified with previously diagnosed but not well controlled asthma and led to $85.55, $12.36, and $2.58 in additional screening, daily treatment, and indirect costs and $5.01 less in emergency department and hospitalization costs. Conclusion Population-based asthma screening is not cost-effective at $50,000 per QALY and has only a 20% chance of being cost-effective at $100,000 per QALY. The most efficient approach is to screen for previously diagnosed but poorly controlled asthma. Linking screening with better treatment, and long-term adherence strategies might yield future cost-effective approaches. |
---|---|
ISSN: | 0091-6749 1097-6825 |
DOI: | 10.1016/j.jaci.2009.12.984 |